The Fusion Biopsy Market is developing alongside advances in medical imaging, molecular diagnostics, and precision medicine. The industry was worth around USD 0.85 billion in 2024 and is expected to grow from USD 0.92 billion in 2025 to USD 1.91 billion by 2035, reflecting a 7.65% CAGR over the 2025–2035 forecast period.

The growing use of minimally invasive procedures is a major factor supporting this expansion. Fusion biopsy combines imaging information to improve the targeting of suspicious areas, while developments in real-time imaging and automated systems are helping enhance procedural accuracy. Increasing research and development spending is also encouraging innovation in biopsy equipment and supporting technologies.

DNA-based technologies hold the largest tech-target share because of their established role in genetic testing and oncology. RNA-based solutions are developing rapidly as researchers focus on gene expression and biomarker discovery. In the product landscape, Multi-gene Panels lead the market, while Companion Diagnostics are benefiting from the growing emphasis on linking diagnostic results with targeted therapies.

Oncology remains the dominant application, while Neurology is emerging as an important area for future development. NGS currently leads the technology segment due to its ability to generate comprehensive genetic information, with PCR continuing to see strong use because of its speed and reliability. Regionally, North America holds about 45% of the market, Europe around 30%, and Asia-Pacific approximately 20%.

Looking ahead, the industry offers opportunities in AI-driven lesion identification, improved image-guided biopsy systems, companion diagnostics, and integrated molecular testing. The combination of better imaging, genomic analysis, and patient-specific treatment planning could expand the role of fusion biopsy across cancer care and other specialized diagnostic applications.